首页> 外文期刊>Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association >Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease
【24h】

Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease

机译:非酒精性脂肪肝患者血脂异常作为心血管危险因素的管理

获取原文
获取原文并翻译 | 示例
           

摘要

Nonalcoholic fatty liver disease (NAFLD) is the most frequent cause of liver disease in the United States and is associated with an increased risk of cardiovascular disease (CVD) and cardiovascular (CV) mortality, independent of traditional cardiovascular risk factors. CVD is one of the most common causes of death among individuals with NAFLD and management of NAFLD must extend beyond liver disease to include CVD risk modification. Clinicians should assess CVD risk with the Framingham Risk Score and screen for CVD risk factors including dyslipidemia, diabetes mellitus, hypertension, tobacco use, and the metabolic syndrome. CVD risk factors, particularly dyslipidemia, require aggressive medical management to reduce the high risk of CVD events and death in individuals with NAFLD.
机译:非酒精性脂肪性肝病(NAFLD)是美国最常见的肝病病因,与心血管疾病(CVD)和心血管疾病(CV)死亡率增加相关,而与传统的心血管疾病危险因素无关。 CVD是NAFLD患者中最常见的死亡原因之一,NAFLD的治疗必须超越肝脏疾病,以包括CVD风险的改变。临床医生应使用Framingham风险评分评估CVD风险,并筛查CVD风险因素,包括血脂异常,糖尿病,高血压,吸烟和代谢综合征。 CVD危险因素,尤其是血脂异常,需要积极的医学管理以降低NAFLD患者发生CVD事件和死亡的高风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号